Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection

In brief

A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.

Key facts

Study ID
NCT05616221
Run by
Armata Pharmaceuticals, Inc.
People needed
48
Starts
2023-01-10
Expected to finish
2024-08-08
Last updated by the study team
2026-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.